Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

  1. Fleishaker, D.L.
  2. Garcia Meijide, J.A.
  3. Petrov, A.
  4. Kohen, M.D.
  5. Wang, X.
  6. Menon, S.
  7. Stock, T.C.
  8. Mebus, C.A.
  9. Goodrich, J.M.
  10. Mayer, H.B.
  11. Zeiher, B.G.
Journal:
Arthritis Research and Therapy

ISSN: 1478-6354,  1478-6362

Year of publication: 2012

Volume: 14

Issue: 1

Type: Article

DOI: 10.1186/AR3685 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus